Cardiovascular risk and its modification in patients with connective tissue diseases

Abstract It is well documented that patients with systemic lupus erythematosus (SLE) are at an increased risk of atherosclerotic cardiovascular (CV) disease. There is evidence that traditional risk factors and disease-related factors are involved in this increased risk. Less is known about CV risk a...

Full description

Saved in:
Bibliographic Details
Published in:Best practice & research. Clinical rheumatology 2016-02, Vol.30 (1), p.81-94
Main Authors: O'Sullivan, Miriam, Bruce, Ian N, Symmons, Deborah P.M
Format: Article
Language:English
Subjects:
Atherosclerosis - etiology
Cardiovascular disease
Cardiovascular Diseases - etiology
Cardiovascular risk management
Connective tissue diseases
Connective Tissue Diseases - complications
Humans
Idiopathic inflammatory myopathies
Lupus Erythematosus, Systemic - complications
Primary Sjögren's syndrome
Rheumatology
Risk Factors
SLE
Systemic sclerosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract It is well documented that patients with systemic lupus erythematosus (SLE) are at an increased risk of atherosclerotic cardiovascular (CV) disease. There is evidence that traditional risk factors and disease-related factors are involved in this increased risk. Less is known about CV risk and outcomes in other connective tissue diseases (CTDs). Future longitudinal observational studies may help to answer these important questions; however, because CTDs are rare, collaboration between clinicians with similar research interests is needed to ensure sufficiently large cohorts are available to address these issues. Here, we review the evidence available for CV risk in CTDs and discuss the benefits of longitudinal observational studies in identifying CV outcomes. Structured care protocols for the management of CV risk in CTDs are lacking. We propose a target-based approach to assessing and managing CV risk in CTDs.
ISSN:1521-6942
1532-1770
DOI:10.1016/j.berh.2016.03.003